Monoclonal antibody treatments have transformed the lives of severe asthma patients. Yet, the lack of comparative trials and real-world usage data poses a challenge for clinicians. Bayside Health Peninsula researcher Professor David Langton set out to fill this gap by evaluating and comparing the performance of Benralizumab and Mepolizumab treatments using real clinic data from …










